Business

Aptamer Group and Bio-Works Technologies have entered into an agreement to develop an affinity resin for improved purification and scale up of gene therapy vectors.  Under the agreement, Aptamer Group will develop an Optimer ligand capable of binding and eluting of a viral vector. Bio-Works Technologies will then develop a derivatised resin by coupling the Optimer to its patented WorkBeads agarose beads.  Optimer ligands […]

Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.   Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that together they can provide a […]

Digital Science has launched a new version of its Dimensions platform – Dimensions Life Sciences & Chemistry – focused on life sciences and chemistry research activities.   Dimensions L&C analyses more than 120 million scientific publications, millions of patents, grants and clinical trial documents. It applies semantic text analysis tools and ontologies, providing powerful up-to-date discovery functionality previously […]

Avacta has appointed Dr Mark Goldberg as Non-executive Director to the Board with immediate effect. Dr Alastair Smith, Chief Executive Officer of Avacta, said Goldberg’s experience as a biotech executive and oncologist will greatly benefit the strategy and vision for the therapeutic business.  Dr Goldberg is a medical oncologist and haematologist on the faculty of Brigham & Women’s Hospital […]

Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.  The company has a pipeline of […]

Sino Biological has announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext. A total of 17 million shares were issued for a total of ¥4.98 billion (US$770 million) raised during this initial public offering.   Sino Biological says the listing is an important milestone in its strategic plan for growth. It signifies a new starting point for the company’s future […]

The National Institutes of Health (NIH) has awarded approximately $53 million in annual funding over the next five years to ten research organisations in a continued effort to find a cure for HIV.   The new awards for the Martin Delaney Collaboratories for HIV Cure Research programme expand the initiative’s 2016 renewal from six institutions to ten. One of the new grants […]

Listen to this article on the DDW Podcast: An expert’s view by John Yoshi Shyu, Ph.D. Corning Life Sciences. Most vaccines are manufactured using technology devised fifty or more years ago, in manufacturing plants that are sometimes even older. The vaccine production process is continually refreshed by new tools and technologies, and that fast-paced innovation gives […]

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be developed into drugs to prevent […]

Listen to this article on the DDW Podcast: By Christopher Doyle, PhD, Director, IBC Services at WCG The Covid-19 pandemic spawned a flurry of research that culminated in the development of several vaccines that express viral proteins from recombinant or synthetic genetic material. The success of these new vaccines thrust the field of human gene transfer […]